



02 November 2021

2021 ANNUAL GENERAL MEETING – CEO’S PRESENTATION

MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) provides the attached CEO Presentation to be delivered at today’s Annual General Meeting commencing at 11.00am AEDT.

The AGM can be joined at <https://meetings.linkgroup.com/HXL21>

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO.

Enquiries:

Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please [click here](#)

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on [Twitter](#) and [LinkedIn](#) or email us at info@hexima.com.au.

ersonal use only

MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER PRESENTATION

MR MICHAEL ALDRIDGE



MAJOR ACHIEVEMENTS FY2021


Milestones & Achievements

- Public Offering and listing on ASX
 - \$3 million offering at A\$0.20 per share
- Phase IIb clinical trial
 - Initiation and completion of enrolment
- Intellectual property protection
- Scientific Advisory Board
 - Australian, US and Japan KOLs



AUSTRALIAN PHASE IIB CLINICAL TRIAL

HXP124-ONY-002



NOTE: DAILY DOSING PERIODS INCLUDE 1-WEEK WASHOUTS EVERY 6 WEEKS

Enrolment
completed
July 2021

- Multi-center, randomised, double blind, vehicle-controlled study
- Primary endpoint safety and tolerability, secondary endpoints Mycological Cure and Clinical Efficacy
- Three active (2% pezadeftide) versus vehicle arms to test optimal dosing strategy
- Safety & efficacy assessed at 13, 24, 36 and 40 weeks, data expected Q2 2022



Strong patent position

ADDITIONAL PROTECTION VIA
FORMULATION PATENTS AND MARKET
EXCLUSIVITY FOR BIOLOGICS

Clearly defined growth strategy

- Develop independently in US and EU (ICH) markets
- License and collaborative development in Japan and potentially China - presently in preliminary discussions with multiple parties

Granted patents
(exp 2035) in major
markets covering the
use of pezadeftide in
the treatment of
onychomycosis



Granted and
pending patents
covering stabilising
formulation for
pezadeftide



12-year US market
exclusivity on FDA
approval likely available
as a biologic drug



LOOKING FORWARD

A PIVOTAL YEAR IN GROWTH AND DEVELOPMENT

Expected Milestones

- Ongoing US focused Phase III preparations
 - Completed \$11 million financing
- Phase IIb clinical trial – data Q2 2022
- Corporate partnership(s)
- Capital raising to fund phase III
- Expansion of development pipeline
- Initiate Phase III clinical trials - late CY2022



Pezadeftide: a potential solution for a large and poorly served market



POORLY SERVED MARKET

Affects 14% of the population
Strong consumer preference for topical products
Clear unmet medical need



NEW AND UNIQUE

Novel molecule with unique mode of action
Strong patent protection and long patent life



SAFE

No systemic effects
No local redness or irritation



CONVENIENT

Easy to apply
Short treatment duration
Rapid clearing of infected nail



EFFECTIVE

Efficiently penetrates the nail
Rapidly kills fungus
Best-in-class mycological cure

